LUPIN · NSE
Lupin Limited
₹2,083
-0.72% (-₹15.1)
Prev. close
₹2,098.1
Volume
11,94,290
Delivery %
76.0%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Lupin Limited
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company also offers products in the therapeutic areas of cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, anti-TB, cephalosporins, and nonsteroidal anti-inflammatory drug therapies. In addition, it provides chronic therapies, and hospital-based products; products for diabetes and iron supplements for anemia, and a Budesonide-Formoterol combination for asthma. Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro rehabilition business. It operates through network consisting of labs and collection centers. The company has a strategic collaboration with TB Alliance to support the clinical development and commercialization of Telacebec for the treatment of tuberculosis, leprosy, and buruli ulcer. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Ms. Vinita D. Gupta
Headquarters
Mumbai
Employees
26,021
Website
lupin.comExchange
View on NSE ↗Key stats
Market cap
₹95,938.96 Cr
P/E ratio (TTM)
17.4
Dividend yield
0.88%
EPS (TTM)
₹120.65
Beta (1Y · daily vs NIFTY 50)
0.53
Beta (5Y · monthly vs NIFTY 50)
0.83
Shares float
24.21 Cr
EPS · quarter ended Jun 2026
₹30.89
Upcoming earnings
05 Nov 2026
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹15,162.96 Cr | ₹16,405.48 Cr | ₹16,641.66 Cr | ₹20,010.82 Cr | ₹22,707.90 Cr | ₹27,958.03 Cr | |
| EBITDA | ₹2,703.17 Cr | ₹428.91 Cr | ₹1,871.48 Cr | ₹3,898.12 Cr | ₹5,479.13 Cr | ₹8,682.54 Cr |
| ₹1,216.53 Cr | ₹-1,528.04 Cr | ₹430.08 Cr | ₹1,914.48 Cr | ₹3,281.62 Cr | ₹5,332.84 Cr | |
| Diluted EPS | ₹26.97 | ₹-33.65 | ₹9.41 | ₹41.87 | ₹71.69 | ₹116.44 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹23,430.00 Cr | ₹21,651.00 Cr | ₹22,800.00 Cr | ₹23,751.00 Cr | ₹28,978.00 Cr | ₹38,146.00 Cr | |
| — | ₹4,158.38 Cr | ₹4,541.52 Cr | ₹2,921.77 Cr | ₹5,447.77 Cr | ₹6,616.18 Cr | |
| Stockholders' equity | ₹13,803.00 Cr | ₹12,153.00 Cr | ₹12,465.00 Cr | ₹14,290.00 Cr | ₹17,203.00 Cr | ₹22,448.00 Cr |
Total debt, Long-term debt, Current (short-term) debt, Others have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,239.38 Cr | ₹1,082.38 Cr | ₹1,897.24 Cr | ₹3,648.36 Cr | ₹2,999.94 Cr | ₹7,334.50 Cr | |
| Investing cash flow | ₹-657.20 Cr | ₹577.16 Cr | ₹-1,286.77 Cr | ₹-1,712.20 Cr | ₹-4,171.89 Cr | ₹-3,864.59 Cr |
| ₹-1,885.00 Cr | ₹-1,572.00 Cr | ₹-337.00 Cr | ₹-2,184.00 Cr | ₹1,732.00 Cr | ₹-846.00 Cr | |
| Capital expenditure | ₹-678.00 Cr | ₹-905.00 Cr | ₹-1,500.00 Cr | ₹-929.00 Cr | ₹-1,682.00 Cr | ₹-2,055.00 Cr |
| End cash position | ₹920.63 Cr | ₹991.37 Cr | ₹1,264.59 Cr | ₹983.76 Cr | ₹1,543.69 Cr | ₹4,167.73 Cr |
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21 | Mar 22 | Jun 22 | Sep 22 | Dec 22 | Mar 23 | Jun 23 | Sep 23 | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25–Sep 25(2Q) | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 46.83% | 46.81% | 46.78% | 47.10% | 47.11% | 47.10% | 47.08% | 47.07% | 47.06% | 47.04% | 47.01% | 46.98% | 46.96% | 46.95% | 46.92% | 46.90% | 46.89% | 46.86% | 46.85% |
| Public | 53.15% | 53.18% | 53.22% | 52.90% | 52.89% | 52.90% | 52.92% | 52.93% | 52.94% | 52.96% | 52.99% | 53.02% | 53.04% | 53.05% | 53.08% | 53.10% | 53.11% | 53.14% | 53.15% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Lupin Limited | ₹93,510.87 Cr | ₹2,098.1 | 16.9 | 4.17 | 23.8% | 0.29 | +23.9% | +3.3% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 30
Concall transcripts
Show all 12
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
56 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.